Logo image of TTNP

TITAN PHARMACEUTICALS INC (TTNP) Stock Fundamental Analysis

NASDAQ:TTNP - Nasdaq - US8883147055 - Common Stock - Currency: USD

3.67  -0.14 (-3.67%)

Fundamental Rating

2

TTNP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of TTNP is average, but there are quite some concerns on its profitability. TTNP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TTNP had negative earnings in the past year.
TTNP had a negative operating cash flow in the past year.
In the past 5 years TTNP always reported negative net income.
TTNP had a negative operating cash flow in each of the past 5 years.
TTNP Yearly Net Income VS EBIT VS OCF VS FCFTTNP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

1.2 Ratios

TTNP's Return On Assets of -163.41% is on the low side compared to the rest of the industry. TTNP is outperformed by 87.03% of its industry peers.
TTNP's Return On Equity of -182.17% is on the low side compared to the rest of the industry. TTNP is outperformed by 69.73% of its industry peers.
Industry RankSector Rank
ROA -163.41%
ROE -182.17%
ROIC N/A
ROA(3y)-143.39%
ROA(5y)-165.71%
ROE(3y)-334.48%
ROE(5y)-533.68%
ROIC(3y)N/A
ROIC(5y)N/A
TTNP Yearly ROA, ROE, ROICTTNP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TTNP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TTNP Yearly Profit, Operating, Gross MarginsTTNP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

TTNP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TTNP has more shares outstanding
TTNP has more shares outstanding than it did 5 years ago.
TTNP has a worse debt/assets ratio than last year.
TTNP Yearly Shares OutstandingTTNP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K
TTNP Yearly Total Debt VS Total AssetsTTNP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -152.67, we must say that TTNP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -152.67, TTNP is not doing good in the industry: 96.22% of the companies in the same industry are doing better.
TTNP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -152.67
ROIC/WACCN/A
WACC9.84%
TTNP Yearly LT Debt VS Equity VS FCFTTNP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 9.71 indicates that TTNP has no problem at all paying its short term obligations.
TTNP has a Current ratio of 9.71. This is amongst the best in the industry. TTNP outperforms 81.08% of its industry peers.
TTNP has a Quick Ratio of 9.71. This indicates that TTNP is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.71, TTNP belongs to the best of the industry, outperforming 81.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.71
Quick Ratio 9.71
TTNP Yearly Current Assets VS Current LiabilitesTTNP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

TTNP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.87%, which is quite good.
Looking at the last year, TTNP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
TTNP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.16% yearly.
EPS 1Y (TTM)15.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.51%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.37%
Revenue growth 5Y-51.16%
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TTNP Yearly Revenue VS EstimatesTTNP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
TTNP Yearly EPS VS EstimatesTTNP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TTNP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TTNP Price Earnings VS Forward Price EarningsTTNP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TTNP Per share dataTTNP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TTNP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TITAN PHARMACEUTICALS INC

NASDAQ:TTNP (2/21/2025, 8:00:01 PM)

3.67

-0.14 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-31 2025-03-31
Inst Owners1.49%
Inst Owner Change-99.99%
Ins Owners43.56%
Ins Owner Change0%
Market Cap3.34M
Analysts43.33
Price TargetN/A
Short Float %4.7%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-6.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-6.18
FCFYN/A
OCF(TTM)-6.18
OCFYN/A
SpS0
BVpS3.55
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -163.41%
ROE -182.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-143.39%
ROA(5y)-165.71%
ROE(3y)-334.48%
ROE(5y)-533.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.71
Quick Ratio 9.71
Altman-Z -152.67
F-Score3
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)4.06%
Cap/Depr(5y)60.41%
Cap/Sales(3y)0.86%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-85.51%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-66.37%
Revenue growth 5Y-51.16%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.87%
OCF growth 3YN/A
OCF growth 5YN/A